Hospital Universitario De Canarias
- Address
- lock Available on a paid plan
Immune System Diseases Research at Hospital Universitario De Canarias
The site is conducting clinical trials in immune system diseases, with a focus on Sjogren's syndrome. This research is aimed at better understanding the condition and evaluating new treatment options that may help improve symptoms and disease control for people living with this chronic autoimmune disorder.
- Studying Sjogren's syndrome to assess whether new therapies can improve overall disease activity and patient outcomes.
- Evaluating treatment effectiveness in autoimmune disease care, with attention to symptom relief and disease management.
These trials reflect a strong interest in advancing care for autoimmune conditions through more effective and targeted treatment strategies.
Nutritional and Metabolic Diseases Research in Kidney Transplantation
Clinical research at this hospital also covers nutritional and metabolic diseases, especially metabolic syndrome in patients waiting for kidney transplantation. The trials are exploring ways to improve metabolic health before transplant and reduce the risk of later complications such as diabetes.
- Focusing on metabolic syndrome in transplant candidates to see whether treatment can help reverse abnormal metabolic changes before surgery.
- Investigating GLP-1 receptor agonists as a preventive approach to support better metabolic control and lower the chance of post-transplant diabetes.
This area of research combines nephrology and metabolic care, with the goal of improving readiness for transplantation and long-term health outcomes.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 22 therapeutic areas and 15 of 288 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 241 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 43 by active trials.
- 1Amgen Inc.3active
lock +42 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Fundacion PETHEMA8trials
lock +28 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 567 other sites in Spain
Therapeutic Area Benchmark — Spain
Select a therapeutic area to compare against other sites in Spain.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Spain
Market Share
Country: Spain
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Hospital Universitario De Canarias
lock Showing 1 of 127 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A multi-center, double-blind, randomized, placebo-controlled, 2-way cross-over post approval study to investigate the efficacy of daridorexant in subjects with insomnia and comorbid nocturia | Idorsia Pharmaceuticals Ltd. | Phase III | Not Recruiting | Mar 2023 | Apr 2024 |
IMP list
lock Showing 1 of 288 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Dexamethasone | 8 | Unknown | 2015-06-15 | 2024-09-26 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.